# US 2019/0167661 A1 · Nanoliposomal Irinotecan for Use in Treating Small Cell Lung Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167661 A1
- Document ID: US20190167661A1
- Status: Published application
- Kind: A1
- Application number: 16/302,050
- Filed: 2017-05-17
- Published: 2019-06-06
- Earliest claimed: 2016-05-18
- Assignees: Ipsen Biopharm Ltd.
- Applicants: Ipsen Biopharm Ltd.
- Inventors: Bambang Adiwijaya; Jonathan Basil Fitzgerald; Helen Lee
- Web page: https://patentgrep.com/patent/US20190167661A1

## CPC

- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 35/00: Antineoplastic agents
- A61K 33/243: Platinum; Compounds thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.

## Claims

### Claim 1

A method of treating a human patient diagnosed with small cell lung cancer (SCLC) following disease progression on or after first-line platinum-based therapy for the SCLC, the method comprising administering to the human patient an antineoplastic therapy once every two weeks, the antineoplastic therapy consisting of a 70 mg/m2 (free base) dose of liposomal irinotecan.

### Claim 2 (depends on 1)

The method of claim 1, wherein the platinum-based therapy comprises the prior, discontinued administration of cisplatin or carboplatin to treat the human patient diagnosed with SCLC.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human patient has a blood ANC greater than 1,500 cells/microliter without the use of hematopoietic growth factors, prior to the administration of the liposomal irinotecan.

### Claim 4 (depends on 1)

The method of claim 1, wherein the human patient has a blood platelet count of greater than 100,000 cells per microliter, prior to the administration of the liposomal irinotecan.

### Claim 5 (depends on 1)

The method of claim 1, wherein the human patient has a blood hemoglobin greater than 9 g/dL, prior to the administration of the liposomal irinotecan.

### Claim 6 (depends on 1)

The method of claim 1, wherein the human patient has a serum creatinine of less than or equal to 1.5×ULN and a creatinine clearance of greater than or equal to 40 mL/min prior to the administration of the liposomal irinotecan.

### Claim 7 (depends on 1)

The method of claim 1, wherein the human patient has not received a topoisomerase I inhibitor prior to administration of the liposomal irinotecan.

### Claim 8 (depends on 1)

The method of claim 1, wherein the human patient has not received more than a single platinum-based therapy prior to administration of the liposomal irinotecan.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antineoplastic therapy comprises the steps of:
(a) preparing a pharmaceutically acceptable injectable composition by combining a dispersion of liposomal irinotecan containing 4.3 mg irinotecan free base/mL of the dispersion with a 5% Dextrose Injection (D5W) or 0.9% Sodium Chloride Injection to obtain the injectable composition having a final volume of 500 mL and 70 mg/m2 (free base) of the liposomal irinotecan (±5%); and
(b) administering the injectable composition from step (a) containing the irinotecan liposome to the patient in a 90-minute infusion.

### Claim 10 (depends on 1)

The method of claim 1, further comprising administering to the human patient dexamethasone and a 5-HT3 blocker prior to each administration of the antineoplastic therapy, and optionally further administering an antiemetic to the human patient.

### Claim 11

A method of treating a human patient who is not homozygous for the UTG1A1*28 allele and is diagnosed with small cell lung cancer (SCLC) following disease progression on or after first-line platinum-based therapy for the SCLC, the method comprising administering to the human patient an antineoplastic therapy once every two weeks in a six-week cycle, the antineoplastic therapy consisting of a 70 mg/m2 (free base) dose of liposomal irinotecan.

### Claim 12 (depends on 11)

The method of claim 11, wherein the platinum-based therapy comprises the prior, discontinued administration of cisplatin or carboplatin to treat the human patient diagnosed with SCLC.

### Claim 13 (depends on 12)

The method of claim 12, wherein the human patient has one or more of the following prior to the administration of the liposomal irinotecan:
(a) a blood ANC greater than 1,500 cells/microliter without the use of hematopoietic growth factors;
(b) a blood platelet count of greater than 100,000 cells per microliter;
(c) a blood hemoglobin greater than 9 g/dL; and
(d) a serum creatinine of less than or equal to 1.5×ULN and a creatinine clearance of greater than or equal to 40 mL/min.

### Claim 14 (depends on 13)

The method of claim 13, wherein the human patient has not received a topoisomerase I inhibitor prior to administration of the liposomal irinotecan; and the human patient has not received more than a single platinum-based therapy prior to administration of the liposomal irinotecan.

### Claim 15 (depends on 13)

The method of claim 13, wherein the method comprises administering the antineoplastic therapy for at least three six-week cycles.

### Claim 16 (depends on 11)

The method of claim 11, wherein the antineoplastic therapy comprises the steps of:
(a) preparing a pharmaceutically acceptable injectable composition by combining a dispersion of liposomal irinotecan containing 4.3 mg irinotecan free base/mL of the dispersion with a 5% Dextrose Injection (D5W) or 0.9% Sodium Chloride Injection to obtain the injectable composition having a final volume of 500 mL and 70 mg/m2 (free base) of the liposomal irinotecan (±5%); and
(b) administering the injectable composition from step (a) containing the irinotecan liposome to the patient in a 90-minute infusion.

### Claim 17 (depends on 16)

The method of claim 16, further comprising administering to the human patient dexamethasone and a 5-HT3 blocker prior to each administration of the antineoplastic therapy, and optionally further administering an antiemetic to the human patient.

### Claim 18

A method of treating a human patient diagnosed with small cell lung cancer (SCLC) following disease progression on or after a first-line platinum-based therapy for the SCLC selected from the group consisting of cisplatin or carboplatin, the method comprising administering to the human patient an antineoplastic therapy once every two weeks for a total of at least three six-week cycles, the antineoplastic therapy consisting of a 70 mg/m2 (free base) dose of liposomal irinotecan;
wherein the human patient is not homozygous for the UTG1A1*28 allele and has the following prior to the administration of each antineoplastic therapy of liposomal irinotecan:
(a) a blood ANC greater than 1,500 cells/microliter without the use of hematopoietic growth factors;
(b) a blood platelet count of greater than 100,000 cells per microliter;
(c) a blood hemoglobin greater than 9 g/dL; and
(d) a serum creatinine of less than or equal to 1.5×ULN and a creatinine clearance of greater than or equal to 40 mL/min.

### Claim 19 (depends on 18)

The method of claim 18, wherein:
(e) the human patient has not received a topoisomerase I inhibitor prior to administration of the liposomal irinotecan and has not received more than a single platinum-based therapy prior to administration of the liposomal irinotecan; and
(f) the method further comprises administering to the human patient dexamethasone and a 5-HT3 blocker prior to each administration of the antineoplastic therapy, and optionally further administering an antiemetic to the human patient.

### Claim 20 (depends on 19)

The method of claim 19, wherein the antineoplastic therapy comprises the steps of:
(i) preparing a pharmaceutically acceptable injectable composition by combining a dispersion of liposomal irinotecan containing 4.3 mg irinotecan free base/mL of the dispersion with a 5% Dextrose Injection (D5W) or 0.9% Sodium Chloride Injection to obtain the injectable composition having a final volume of 500 mL and 70 mg/m2 (free base) of the liposomal irinotecan (±5%); and
(ii) administering the injectable composition from step (i) containing the irinotecan liposome to the patient in a 90-minute infusion.
